Phathom Pharmaceuticals, Inc. PHAT
5.68 USD -0.06 (-1.05%)
At closeNov 4, 2026, 4:00 PM EST
5.68 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
5.66 Day range 6.13
5.02 52-week range 18.31
- YTD
- -65.76%
- 1 year
- -57.89%
- Market cap
- 461.74M
- Revenue (ttm)
- 175.11M
- Profit margin
- -126.35%
- EPS (ttm)
- -1.01
- Shares out
- 79.43M
- Forward P/E
- 7.60
- YTD return
- -65.76%
- 1-year return
- -57.89%
- Volume
- 1.50M
- Avg volume
- 1.45M
- Open
- 5.95
- Previous close
- 5.74
- Day's range
- 5.66 – 6.13
- 52-week range
- 5.02 – 18.31
- Beta
- 0.61
- Analysts
- Strong Buy
- Price target
- 23.70 (+317.3%)
2Y -12.69 (-69.08%)
Key statistics
- Enterprise value
- 1.47B
- PEG ratio
- 0.00
- Price / sales
- 5.32
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 94.10%
- Free cash flow
- -107.86M
- Total cash
- 129.97M
- Total debt
- 589.17M
- Return on equity
- 0.00%
- Short % of float
- 14.11%
- 50-day average
- 11.63
- 200-day average
- 12.45
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.70 +317.3% upside
Now 5.68
- Target (low)
- 13.00
- Target (mean)
- 23.70
- Target (high)
- 29.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1954.
Financials — quick view
PHAT Revenue — quarterly 84.72M
PHAT Net income — quarterly -13.90M
PHAT EPS — quarterly -0.16
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Barclays | up | Equal-Weight | Overweight |
| Feb 27, 2026 | Guggenheim | main | Buy | Buy |
| Dec 9, 2025 | Barclays | init | — | Equal-Weight |
| Oct 31, 2025 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 9, 2025 | Craig-Hallum | main | Buy | Buy |
| Jun 9, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- phathompharma.com
News
Phathom Pharmaceuticals to Participate in November Investor Conferences 
Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx 
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx 
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call 
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript 
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates 
Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript 
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est 
Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate 
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Your note
Sign in to keep a note on PHAT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASTA STEVEN L | Chief Executive Officer | Stock Award(Grant) | Feb 9, 2026 | 373,315 |
| BREEDLOVE ROBERT CHARLES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,425 |
| COOK ANNE MARIE | Officer | Stock Award(Grant) | Feb 9, 2026 | 88,660 |
| CURRAN TERRIE | President | Sale | Jan 20, 2025 | 364,305 |
| HENDERSON MOLLY | Chairman of the Board | Sale | Apr 6, 2025 | 91,779 |
| NABULSI AZMI M.D. | Chief Operating Officer | Stock Award(Grant) | Feb 26, 2025 | 1,101,870 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 15.69% | 12,466,489 | 146.23M | Dec 30, 2025 |
| Medicxi Ventures Management (Jersey) Ltd | 9.40% | 7,464,572 | 87.56M | Mar 30, 2026 |
| Invesco Ltd. | 4.94% | 3,920,446 | 45.99M | Dec 30, 2025 |
| Blackrock Inc. | 4.48% | 3,555,548 | 41.71M | Dec 30, 2025 |
| Carlyle Group Inc. | 4.40% | 3,496,808 | 41.02M | Dec 30, 2025 |
| Vanguard Group Inc | 4.00% | 3,177,211 | 37.27M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIM Intl Mutual Fd.s -Invesco Global Fd. | 2.95% | 2,342,451 | 27.48M | Jan 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.29% | 1,821,569 | 21.37M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.24% | 982,131 | 11.52M | Feb 27, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 1.22% | 968,545 | 11.36M | Feb 27, 2026 |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 0.94% | 749,134 | 8.79M | Dec 30, 2025 |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | 0.71% | 563,443 | 6.61M | Dec 30, 2025 |